No, Simvastatin and Atorvastatin Should Not Be Taken Together
Taking simvastatin and atorvastatin together is not recommended and serves no therapeutic purpose, as both are statins from the same drug class that work through the same mechanism (HMG-CoA reductase inhibition). Combining them would only increase the risk of statin-related adverse effects—particularly myopathy and rhabdomyolysis—without providing additional cardiovascular benefit.
Why This Combination Makes No Clinical Sense
Redundant Mechanism of Action
- Both drugs inhibit the same enzyme (HMG-CoA reductase) to lower cholesterol
- There is no evidence that combining two statins provides additive lipid-lowering benefit
- The lipid-lowering effect plateaus with higher doses of a single statin rather than requiring combination therapy
Increased Risk Without Benefit
- Combining statins would exponentially increase the risk of muscle toxicity 1
- Both simvastatin and atorvastatin are metabolized via CYP3A4, creating overlapping toxicity pathways
- The FDA labeling for simvastatin explicitly warns about myopathy and rhabdomyolysis risk, which would be compounded by dual statin therapy 1
What the Evidence Shows About Switching (Not Combining)
The research literature addresses switching between these statins, not combining them:
- Studies demonstrate that patients can be safely converted from simvastatin to atorvastatin when simvastatin is inadequate or poorly tolerated 2
- Atorvastatin generally provides greater LDL-cholesterol reduction than equivalent doses of simvastatin (atorvastatin 10 mg vs simvastatin 20 mg showed 37.1% vs 35.4% LDL reduction) 3
- When patients experience myalgias or elevated creatine kinase on simvastatin, switching to atorvastatin often resolves these issues 2
The Correct Clinical Approach
If current statin therapy is inadequate:
- Uptitrate the current statin to the maximum tolerated dose
- Switch to a more potent statin (e.g., simvastatin to atorvastatin or rosuvastatin)
- Add a non-statin agent (ezetimibe, PCSK9 inhibitor, bempedoic acid) if monotherapy at maximum dose is insufficient
Never combine two statins—this represents a fundamental misunderstanding of statin pharmacology and unnecessarily endangers the patient.
Common Pitfall to Avoid
Do not confuse the concept of "combination lipid therapy" (statin + ezetimibe, for example) with combining two statins. The former is evidence-based; the latter is contraindicated by basic pharmacologic principles and would be considered a prescribing error.